We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.16 | -0.13% | 127.35 | 55,902 | 13:43:18 |
From May 2019 to May 2024
By Dave Sebastian
Merck & Co. Inc. said it expects to move ahead with its Phase 3 trial to assess islatravir as an HIV treatment and prevention by early 2021.
The study will look into the once-monthly pre-exposure prophylaxis treatment option in women and adolescent girls at risk of contracting the virus that causes AIDS in sub-Saharan Africa, the pharmaceutical company said Monday.
The company said it is working with the Bill & Melinda Gates Foundation on the study. The foundation will provide grants to the International Clinical Research Center at the University of Washington Department of Global Health, which is collaborating with Merck on the study, the company said. Merck didn't disclose the amount of the foundation's contribution.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
November 16, 2020 07:12 ET (12:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
